ASPYRE®’s comprehensive lung panel simultaneously analyzes DNA and RNA from blood or tissue in a single assay, enabling straightforward, precise identification of all NCCN guideline recommended genomic biomarkers associated with approved targeted therapies for NSCLC.
Actionable results
ASPYRE accelerates and simplifies analysis by eliminating the noise from genomic data, ensuring accuracy for the markers that are of interest, allowing more confident decision-making.
Cost effective
ASPYRE’s unique capabilities enable guideline-compliant genomic biomarker testing at a fraction of the cost of NGS.
Fast time to treatment
ASPYRE dramatically simplifies and accelerates the detection of actionable biomarkers, enabling patients to go from diagnosis to targeted treatment options with fewer side effects in days not weeks.
Ultra-sensitive
With the ability to detect as little as one molecule of mutated DNA or RNA, ASPYRE is up to 10 times more sensitive than NGS and 50 times more sensitive than single gene PCR tests enabling more accurate and effective patient care.
Read more about how the unique molecular biology behind ASPYRE overcomes the limitations of PCR and NGS to increase access to comprehensive biomarker testing.
Impact of treatment delays
Learn more about the impact of treatment delays caused by the slow turnaround time of biomarker testing.
The barriers to biomarker testing
Learn more about the barriers that are preventing more than 50% of cancer patients from accessing recommended biomarker testing.
Business development representative
If you would like to speak with a representative to learn more about ASPYRE click here.
